1-17 of 17
Swetha Kambhampati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Swetha Kambhampati, Hai-Lin Wang, Jiali Yan, Alex F. Herrera, Matthew J. Frank, Leslie L. Popplewell, Nausheen Ahmed, Yi Lin, Frederick L. Locke, Paola Ghione, John G. Gribben, Timothy Best, Christine Fu, Sara Beygi, Markqayne D Ray, John Bian, Zhen-Huan Hu, Fang Sun, Marcelo Pasquini, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 2121.
https://doi.org/10.1182/blood-2023-178629
Published: 2023
Journal Articles

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Matthew G. Mei, Lu Chen, Sandrine Puverel, L. Elizabeth Budde, Swetha Kambhampati, Shari Daniels, Bev Dunning, Melissa Banez, Larry W. Kwak, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 1697.
https://doi.org/10.1182/blood-2023-190753
Published: 2023
Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Swetha Kambhampati, Reid W. Merryman, Yan Wang, Evandro Bezerra, Timothy Voorhees, Ayo S Falade, Madhav R Seshadri, Megumi Bailey, Neil Bailey, Krish Patel, Charalambos Andreadis, Adam S Kittai, Caron A Jacobson, Joycelynne Michelle Palmer, Annette Brown, Alex F. Herrera, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 3511.
https://doi.org/10.1182/blood-2023-182467
Published: 2023
Journal Articles

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

L. Elizabeth Budde, Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Swetha Kambhampati, Alan Macias, Teresa Kim, Sylvia Dulan, Baishakhi Barva, Sandrine Puverel, Katrin Tiemann, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak
Journal: Blood
Blood (2023) 142 (Supplement 1): 221.
https://doi.org/10.1182/blood-2023-183032
Published: 2023
Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Swetha Kambhampati, Nausheen Ahmed, Mehdi Hamadani, Soyoung Kim, Michael T. Hemmer, Natalie S. Grover, Mazyar Shadman, Amer Beitinjaneh, L. Elizabeth Budde, James Gerson, Caron A. Jacobson, Frederick L. Locke, Dwivedy S. Nasta, Michael L. Wang, Wen-Kai Weng, Jiali Yan, Ana Nunes, David Dalton, James J. Wu, Amina Abdeldaim, Zhen-Huan Hu, Marcelo Pasquini, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 107.
https://doi.org/10.1182/blood-2023-179269
Published: 2023
Journal Articles

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States

Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E. Drolen, Tatyana Feldman, Tarek Haykal, Caroline A. Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Kim, Alexandra Drakaki, Michael Morse, Douglas B. Johnson, Ankit Mangla, Chris Dittus, Praful Ravi, Paul G. Rubinstein, Sarvari V. Yellapragada, Ann LaCasce, Guru P. Sonpavde, Abdul Rafeh Naqash, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 3071.
https://doi.org/10.1182/blood-2023-174589
Published: 2023
Journal Articles

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Clinical Trials & Observations
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam
Journal: Blood
Blood (2022) 140 (25): 2697–2708.
https://doi.org/10.1182/blood.2022016624
Published: 2022
Includes: Supplemental data
Journal Articles

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Swetha Kambhampati, Matthew Mei, Lu Chen, Sandrine Puverel, Robert Chen, Leslie L. Popplewell, Liana Nikolaenko, Lacolle Peters, Saro H. Armenian, Larry W. Kwak, Steve T Rosen, Stephen J Forman, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 9418–9419.
https://doi.org/10.1182/blood-2022-157623
Published: 2022
Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Lu Chen, Jennifer L. Crombie, Jonathon B. Cohen, Ranjana H. Advani, Ann S. LaCasce, Leslie L. Popplewell, Sandrine Puverel, Lacolle Peters, Shari Daniels, James Godfrey, Geoffrey Shouse, Matthew Mei, Swetha Kambhampati, L. Elizabeth Budde, Liana Nikolaenko, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Matthew J. Matasar
Journal: Blood
Blood (2022) 140 (Supplement 1): 1065–1067.
https://doi.org/10.1182/blood-2022-165699
Published: 2022
Journal Articles

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G. Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam
Journal: Blood
Blood (2022) 140 (19): 2024–2036.
https://doi.org/10.1182/blood.2022016747
Published: 2022
Includes: Supplemental data
Journal Articles

A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Pallawi Torka, Swetha Kambhampati, Alexandra Muir, Kirsten Orand, Lynne Smith, Alex F. Herrera, Lionel Lewis, Francisco J. Hernandez-Ilizaliturri, Lu Chen, Alexey V. Danilov
Journal: Blood
Blood (2021) 138 (Supplement 1): 2433.
https://doi.org/10.1182/blood-2021-146345
Published: 2021
Journal Articles

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Brian T. Hill, Caroline J Roth, Rachel Kositsky, Tushar Dave, Cassandra Love, Matthew McKinney, Ahmed Galal, Jadee L Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George L. Chen, Francisco J. Hernandez-Ilizaliturri, Joanna C. Zurko, Ashley Cunningham, Nirav N. Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre H. Goy, Swetha Kambhampati, Robert S. Ohgami, Charalambos Andreadis, Elizabeth Thacker, Chrissie Rozzi, Clay Parker, Lanie Happ, Sandeep S. Dave
Journal: Blood
Blood (2021) 138 (Supplement 1): 165.
https://doi.org/10.1182/blood-2021-145764
Published: 2021
Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-138940
Published: 2020
Journal Articles

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Swetha Kambhampati, MD, Sandy W. Wong, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Priya Choudhry, PhD, William Karlon, MD PhD, Arun P. Wiita, MD PhD, Nina Shah, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-138869
Published: 2020
Journal Articles

Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma

Anna L. Parks, MD, Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Charalambos Andreadis, MD, Lissa Gray, MSN, Sandy W. Wong, MD, Nina Shah, MD, Margaret C. Fang, MD MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 7.
https://doi.org/10.1182/blood-2020-136782
Published: 2020
Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2828.
https://doi.org/10.1182/blood-2019-123279
Published: 2019
Journal Articles

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma

Swetha Kambhampati, MD, Derek Galligan, MD, Guy Ledergor, MD, Thomas G. Martin, III, MD, Jeffrey Wolf, Sandy W. Wong, Nina D. Shah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5576.
https://doi.org/10.1182/blood-2019-122383
Published: 2019